US regulatory status: approved.
biotech · Ataxia Telangiectasia · Ataxia Telangiectasia (A-T) · QNCX
Quince Therapeutics
Quince Therapeutics drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
South San Francisco, USA HQ
2012 Founded
21 Employees
Public company Type
QNCX · NYSE Ticker
Company details
- Status
- Public
- HQ
- South San Francisco, USA
- Founded
- 2012
- Employees
- 21
- Programs
- 10
- Drugs
- 8
- Patents
- 1
Quince Therapeutics pipeline
Portfolio lens on 8 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Quince Therapeutics drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.
- Mechanism
- Dihydrofolate reductase inhibitor
-
Development asset linked to Quince Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to Quince Therapeutics in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to Quince Therapeutics in public FDA and regional records.
-
US regulatory status: approved.